icon-folder.gif   Conference Reports for NATAP  
 
  66th Annual Meeting of the
American Association for the
Study of Liver Diseases
Boston, MA Nov 13-17 2015
Back grey_arrow_rt.gif
 
 
 
Efficacy, Change in MELD Score, and Safety by Baseline MELD Score in Patients With Compensated Cirrhosis Receiving Ombitasvir/Paritaprevir/r and Dasabuvir Plus Ribavirin in the Phase 3 TURQUOISE-II Trial
 
 
  Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
 
Ira Jacobson1, TM Welzel2, Hugo E Vargas3, Marcos Pedrosa4, Norah Terrault5, Douglas Dieterich6, Fredric D Gordon7, Kris V Kowdley8, Guy Neff 4*, Ran Liu4, Juan Carlos Lopez-Talavera4*, Stefan Zeuzem2
1Weill Cornell Medical College, New York, New York, United States; 2JW Goethe University, Frankfurt, Germany; 3Mayo Clinic Arizona, Phoenix, Arizona, United States; 4AbbVie Inc., North Chicago, Illinois, United States; 5University of California San Francisco, San Francisco, California, United States; 6Mount Sinai School of Medicine, Icahn School of Medicine at Mount Sinai, New York, New York, United States; 7Lahey Hospital & Medical Center, Burlington, Massachusett s, United States; 8Liver Care Network, Swedish Medical Center, Seatt le, Washington, United States

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif

AASLD10.gif

AASLD11.gif